Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion

Active Ingredient:
ATC code: 
J01CR05
{info_black}
About Medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine.
{info_black}
Last updated on emc: 17 Nov 2025

Below is a text only representation of the Patient Information Leaflet (ePIL).

The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on {phone} 0800 198 5000. The product code(s) for this leaflet is: PL 44095/0025.

Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion

Package leaflet: Information for the user

Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion

piperacillin/tazobactam

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion is and what it is used for
2. What you need to know before you use Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion
3. How to use Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion
4. Possible side effects
5. How to store Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion
6. Contents of the pack and other information

1. What Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion is and what it is used for

Piperacillin belongs to the group of medicines known as “broad-spectrum penicillin antibiotics”. It can kill many kinds of bacteria. Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion can prevent some resistant bacteria from surviving the effects of piperacillin. This means that when piperacillin and tazobactam are given together, more types of bacteria are killed.

Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion is used in adults and adolescents aged above 12 years to treat bacterial infections, such as those affecting the lower respiratory tract (lungs), urinary tract (kidneys and bladder), abdomen, skin or blood. Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion may be used to treat bacterial infections in patients with low white blood cell counts (reduced resistance to infections).

Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion is used in children aged 2-12 years to treat infections of the abdomen such as appendicitis, peritonitis (infection of the fluid and lining of the abdominal organs), and gallbladder (biliary) infections. Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion may be used to treat bacterial infections in patients with low white blood cell counts (reduced resistance to infections).

In certain serious infections, your doctor may consider using Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion in combination with other antibiotics.

2. What you need to know before you use Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion
Do not use Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion:
  • if you are allergic to piperacillin or tazobactam, or any of the other ingredients of this medicine (listed in section 6)
  • if you are allergic to antibiotics known as penicillins, cephalosporins or other beta-lactamase inhibitors, as you may be allergic to Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion

Warnings and precautions

Talk to your doctor, pharmacist or nurse before using Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion

  • if you have allergies. If you have several allergies, make sure you tell your doctor or other healthcare professional before receiving this product.
  • if you are suffering from diarrhoea before, or if you develop diarrhoea during or after your treatment. In this case, make sure you tell your doctor or other healthcare professional immediately. Do not take any medicine for the diarrhoea without first checking with your doctor.
  • if you have low levels of potassium in your blood. Your doctor may want to check your kidneys before you take this medicine and may perform regular blood tests during treatment.
  • if you have kidney or liver problems, or are receiving haemodialysis. Your doctor may want to check your kidneys before you take this medicine, and may perform regular blood tests during treatment.
  • if you are taking another antibiotic called vancomycin at the same time as Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion, this may increase the risk of kidney injury (see also Other medicines and Piperacillin/Tazobactam 4 g/ 0.5 g powder for solution for infusion in this leaflet).
  • if you are taking certain medicines (called anticoagulants) to avoid an excess of blood clotting (see also Other medicines and Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion in this leaflet) or any unexpected bleeding occurs during the treatment. In this case, you should inform your doctor or other healthcare professional immediately.
  • if you develop convulsions during the treatment. In this case, you should inform your doctor or other healthcare professional.
  • if you think you developed a new or worsening infection. In this case, you should inform your doctor or other healthcare professional.
  • Haemophagocytic lymphohistiocytosis
    There have been reports about a disease in which the immune system makes too many of otherwise normal white blood cells called histiocytes and lymphocytes, resulting in inflammation (haemophagocytic lymphohistiocytosis). This condition may be life-threatening if not diagnosed and treated early. If you experience multiple symptoms such as fever, swollen glands, feeling weak, feeling lightheaded, shortness of breath, bruising, or skin rash, contact your doctor immediately.

Children

Piperacillin / tazobactam is not recommended for use in children below the age of 2 years due to insufficient data on safety and effectiveness.

Other medicines and Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion

Please tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription. Some medicines may interact with piperacillin and tazobactam.

These include:

  • medicine for gout (probenecid). This can increase the time it takes for piperacillin and tazobactam to leave your body.
  • medicines to thin your blood or to treat blood clots (e.g. heparin, warfarin or aspirin).
  • medicines used to relax your muscles during surgery. Tell your doctor if you are going to have a general anaesthetic.
  • methotrextate (medicine used to treat cancer, arthritis or psoriasis). Piperacillin and tazobactam can increase the time it takes for methotrexate to leave your body.
  • medicines that reduce the level of potassium in your blood (e.g. tablets enhancing urination or some medicines for cancer).
    • medicines containing the other antibiotics tobramycin, gentamicin or vancomycin. Tell your doctor if you have kidney problems. Taking Piperacillin/tazobactam and vancomycin at the same time may increase the risk of kidney injury even if you have no kidney problems.

Effect on laboratory tests

Tell the doctor or laboratory staff that you are taking Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion if you have to provide a blood or urine sample.

Pregnancy and breast–feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or other healthcare professional for advice before receiving this medicine. Your doctor will decide if Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion is right for you.

Piperacillin and tazobactam can pass to a baby in the womb or through breast milk. If you are breast-feeding, your doctor will decide if Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion is right for you.

Driving and using machines

The use of Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion is not expected to affect the ability to drive or use machines.

Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion contains sodium

This medicinal product contains 217 mg (9.44 mmol) sodium per vial, equivalent to 10.8% of the WHO recommended maximum daily intake of 2g sodium for an adult.

3. How to use Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion

Your doctor or other healthcare professional will give you this medicine through an infusion (a drip for 30 minutes) into one of your veins.

Dosage
  • The dose of medicine given to you depends on what you are being treated for, your age, and whether or not you have kidney problems.

Adults and adolescents above 12 years old

The usual dose is 4 g/0.5 g piperacillin/tazobactam given every 6-8 hours, which is given into one of your veins (directly into the blood stream)

Children aged 2 to 12 years

The usual dose for children with abdominal infections is 100 mg / 12.5 mg / kg of body weight of piperacillin / tazobactam given every 8 hours into one of your veins (directly into the blood stream). The usual dose for children with low white blood cell counts is 80 mg / 10 mg / kg of body weight of piperacillin / tazobactam given every 6 hours into one of your veins (directly into the blood stream).

Your doctor will calculate the dose depending on your child’s weight but each individual dose will not exceed 4 g / 0.5 g of Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion.

You will be given Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion until the sign of infection has gone completely (5 to 14 days).

Patients with kidney problems

Your doctor may need to reduce the dose of Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion or how often you are given it. Your doctor may also want to test your blood to make sure that your treatment is at the right dose, especially if you have to take this medicine for a long time.

If you receive more Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion than you should

As you will receive Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion from a doctor or other healthcare professional, you are unlikely to be given the wrong dose. However, if you experience side effects, such as convulsions, or think you have been given too much, tell your doctor immediately.

If you miss a dose of Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion

If you think you have not been given a dose of Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion, tell your doctor or other healthcare professional immediately.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

See a doctor immediately if you experience any of these potentially serious side effects of Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion:

The serious side effects (with frequency in brackets) of Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion are:

  • serious skin rashes [Stevens-Johnson syndrome, dermatitis bullous (Not known), toxic epidermal necrolysis (Rare)] appearing initially as reddish target-like spots or circular patches often with central blisters on the trunk. Additional signs include ulcers in the mouth, throat, nose, extremities, genitals and conjunctivitis (red and swollen eyes). The rash may progress to widespread blistering or peeling of the skin and potentially may be life-threatening
  • severe potentially fatal allergic condition (drug reaction with eosinophilia and systemic symptoms) that can involve the skin and most importantly other organs under the skin such as the kidney and the liver
  • a skin condition (acute generalised exanthematous pustulosis) accompanied by fever, which consists of numerous tiny fluid filled blisters contained within large areas of swollen and reddened skin
  • swelling of the face, lips, tongue or other parts of the body (Not known)
  • shortness of breath, wheezing or trouble breathing (Not known)
  • severe rash or hives (Uncommon), itching or rash on the skin (Common)
  • yellowing of the eyes or skin (Not known)
  • damage to blood cells [the signs include: being breathless when you do not expect it, red or brown urine (Not known), nosebleeds (Rare) and small spot bruising (Not known)], severe decrease in white blood cells (Rare)
  • severe or persistent diarrhoea accompanied by a fever or weakness (Rare).

If any of the following side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or other healthcare professional.

Very common side effects (may affect more than 1 in 10 people):

  • diarrhoea

Common side effects (may affect up to 1 in 10 people):

  • yeast infection
  • decrease in platelets, decrease of red blood cells or blood pigment / haemoglobin, abnormal lab test (positive direct Coombs), prolonged blood clotting time (activated partial thromboplastin time prolonged)
  • decrease in blood protein
  • headache, sleeplessness
  • abdominal pain, vomiting, nausea, constipation, upset stomach
  • increase in blood liver enzymes
  • skin rash, itching
  • abnormal kidney blood tests
  • fever, injection site reaction

Uncommon side effects (may affect up to 1 in 100 people):

  • decrease in white blood cells (leukopenia), prolonged blood clotting time (prothrombin time prolonged)
  • decreased blood potassium, decreased blood sugar
  • fits (convulsions) seen in patients on high doses or with kidney problems
  • low blood pressure, inflammation of the veins (felt as tenderness or redness in the affected area), reddening of skin
  • increase of a blood pigment breakdown product (bilirubin)
  • skin reactions with redness, formation of skin lesions, nettle rash
  • joint and muscle pain
  • chills

Rare side effects (may affect up to 1 in 1,000 people):

  • severe decrease in white blood cells (agranulocytosis), bleeding of the nose
  • serious infection of the colon, inflammation of the mucous lining of the mouth
  • detachment of the top layer of the skin all over the body (toxic epidermal necrolysis)

Not known side effects (frequency cannot be estimated from the available data):

  • severe decrease of red blood cells, white blood cells and platelets (pancytopenia), decrease in white blood cells (neutropenia), decrease of red blood cells due to premature breakdown or degradation, small spot bruising, bleeding time prolonged, increase of platelets, increase of a specific type of white blood cells (eosinophilia)
  • allergic reaction and severe allergic reaction
  • inflammation of the liver, yellow staining of the skin or whites of the eyes
  • serious body wide allergic reaction with skin and mucous lining rashes, blistering and various skin eruptions (Stevens-Johnson Syndrome), severe allergic condition involving skin and other organs such as the kidney and the liver (drug reaction with eosinophilia and systemic symptoms), numerous tiny fluid filled blisters contained within large areas of swollen and reddened skin accompanied by fever (acute generalised exanthematous pustulosis), skin reactions with blistering (dermatitis bullous), purpura
  • poor kidney functions and kidney problems
  • a form of lung disease where eosinophils (a form of white blood cell) appear in the lung in increased numbers.
  • Acute disorientation and confusion (delirium)

Piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients.

Beta-lactam antibiotics, including piperacillin tazobactam, may lead to signs of altered brain function (encephalopathy) and convulsions.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and vial after “EXP”. The expiry date refers to the last day of that month.

Unopened vials: This medicinal product does not require any special storage conditions.

For single use only. Discard any unused solution.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information
What Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion contains
  • The active substances are piperacillin and tazobactam.
    Each vial contains 4 g piperacillin (as piperacillin sodium) and 0.5 g tazobactam (as tazobactam sodium).
  • This medicine does not include any other ingredient.

What Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion looks like and the contents of the pack

Piperacillin/Tazobactam 4 g/0.5 g powder for solution for infusion comes in packs containing one small bottle of powder which must be dissolved into a solution before it is given to you by infusion (a slow ‘drip’) into your vein.

Packs containing 1 vial; 10 vials (clinical package); 50 vials (clinical package); 100 vials (clinical package).

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing authorisation holder

Reig Jofre UK Limited
Follaton House
Plymouth Road
Totnes
Devon
TQ9 5NE
UK

Manufacturer

Laboratorio Reig Jofre SA
C/ Jarama 111 Pol.Ind
45007
Toledo
Spain

This medicinal product is authorized in the Member States of the EEA under the following names:

Denmark Piperacillin/Tazobactam Reig Jofre

Finland Piperacillin/Tazobactam Reig Jofre

France PIPERACILLINE / TAZOBACTAM REIG JOFRE 4 g/0,5 g, poudre pour solution pour perfusion

Italy Piperacillina/Tazobactam Reig Jofre

Norway Piperacillin/Tazobactam Reig Jofre

Poland Piperacylina + Tazobaktam Reig Jofre

Sweden Piperacillin/Tazobactam Reig Jofre

United Kingdom Piperacillin/Tazobactam

This leaflet was last revised in 10/2025.

Reig Jofre UK Ltd
Company image
Address
Follaton House, Plymouth Road, Totnes, Devon, TQ9 5NE, UK
Telephone
01803 300401
Medical Information Direct Line
0330 1359 434
Medical Information e-mail
[email protected]
Customer Care direct line
01803 300401
Stock Availability
[email protected]
Stock Availability
[email protected]